Arcturus Therapeutics Holdings Inc.

ARCT Healthcare Biotechnology

Arcturus Therapeutics Holdings Inc.’s revenue for fiscal 2025 (year ended December 2025) was $82.0 million, down 46.1% from fiscal 2024. In the quarter to June 2026, revenue fell 89.5%, EPS fell 147.1% and free cash flow fell 245.7%, each against the same quarter a year earlier.

10.34 0.93 −8.25%
Market cap
$320.3M
P/E
0.0×
Fwd P/E
−1.9×
Dividend yield
—
F-score
2/9
Altman Z
−0.61
Beneish M
−1.29
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

3 2 3 2
ROE
(27.43%) (28.92%) (37.01%) (46.31%)
ROA
(20.43%) (21.39%) (27.26%) (34.96%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(29.66%) (31.06%) (41.72%) (55.20%)
Average Days of Receivables
29.73 24.76 8.96 22.53
Free Cash Flow per Share
(2.16) (2.72) (2.06) (2.56)
Free Cash Flow
(58.65) (74.50) (58.63) (72.77)
Other line items

Show all line items

Columns are period end dates